Key result
Intravenous vasopressors appear to have a relatively low risk of arrhythmogenicity, though dopamine and epinephrine have been associated with arrhythmias in humans.
Why the study?
Do intravenous vasopressors cause proarrhythmic effects in clinical and preclinical settings?
Population
In vitro, ex vivo, animal, and human studies evaluating intravenous vasopressors
Design
Systematic_review
Authors
Loading...
Vasopressor proarrhythmic risks warrant caution in vulnerable patients; leaves open need for updated prospective safety data.
Do intravenous vasopressors cause proarrhythmic effects in clinical and preclinical settings?
While dopamine and epinephrine carry some proarrhythmic risk, phenylephrine and methoxamine may be protective against arrhythmias, though robust controlled human data are lacking.
Tisdale et al. (1995) conducted a review in Proarrhythmic effects. Intravenous vasopressors (dopamine, epinephrine, norepinephrine, phenylephrine, methoxamine) was evaluated on Electrophysiologic and proarrhythmic effects. Intravenous vasopressors appear to have a relatively low risk of arrhythmogenicity, though dopamine and epinephrine have been associated with arrhythmias in humans.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: